- Home
- CRVO vs RLMD Comparison
CRVO vs RLMD Comparison
Compare CRVO & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- RLMD
- Stock Information
- Founded
- CRVO 2001
- RLMD 2004
- Country
- CRVO United States
- RLMD United States
- Employees
- CRVO N/A
- RLMD N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- RLMD Health Care
- Exchange
- CRVO Nasdaq
- RLMD Nasdaq
- Market Cap
- CRVO 67.4M
- RLMD 66.7M
- IPO Year
- CRVO N/A
- RLMD N/A
- Fundamental
- Price
- CRVO $8.50
- RLMD $1.99
- Analyst Decision
- CRVO Strong Buy
- RLMD Hold
- Analyst Count
- CRVO 6
- RLMD 2
- Target Price
- CRVO $19.17
- RLMD $1.00
- AVG Volume (30 Days)
- CRVO 92.4K
- RLMD 517.7K
- Earning Date
- CRVO 11-11-2025
- RLMD 11-06-2025
- Dividend Yield
- CRVO N/A
- RLMD N/A
- EPS Growth
- CRVO N/A
- RLMD N/A
- EPS
- CRVO N/A
- RLMD N/A
- Revenue
- CRVO $7,776,968.00
- RLMD N/A
- Revenue This Year
- CRVO N/A
- RLMD N/A
- Revenue Next Year
- CRVO N/A
- RLMD N/A
- P/E Ratio
- CRVO N/A
- RLMD N/A
- Revenue Growth
- CRVO N/A
- RLMD N/A
- 52 Week Low
- CRVO $1.80
- RLMD $0.24
- 52 Week High
- CRVO $16.94
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- CRVO 51.94
- RLMD 59.73
- Support Level
- CRVO $7.90
- RLMD $1.89
- Resistance Level
- CRVO $8.93
- RLMD $2.84
- Average True Range (ATR)
- CRVO 0.42
- RLMD 0.28
- MACD
- CRVO 0.06
- RLMD 0.01
- Stochastic Oscillator
- CRVO 84.30
- RLMD 37.96
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.